Yahoo Finance Profound Medical First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Profound Medical (TSE:PRN) First Quarter 2024 Results
Key Financial Results
Net loss: US$6.20m (loss narrowed by 8.0% from 1Q 2023).
US$0.26 loss per share (improved from US$0.32 loss in 1Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Profound Medical EPS Beats Expectations, Revenues Fall Short
Revenue missed analyst estimates by 23%. Earnings per share (EPS) exceeded analyst estimates by 14%.
Looking ahead, revenue is forecast to grow 44% p.a. on average during the next 3 years, compared to a 8.1% growth forecast for the Medical Equipment industry in North America.
Performance of the market in Canada.
The company's shares are up 5.0% from a week ago.
Risk Analysis
Before you take the next step you should know about the 2 warning signs for Profound Medical that we have uncovered.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
